NCT03440970 is a EARLY_PHASE1 clinical trial of Lysine Chloride in Decompensated Heart Failure, sponsored by Yale University.

Who is sponsoring NCT03440970?

NCT03440970 is sponsored by Yale University.

What drugs are being tested in NCT03440970?

Interventions in NCT03440970: Lysine Chloride, Placebo.

What condition does NCT03440970 study?

NCT03440970 studies Decompensated Heart Failure.

Is NCT03440970 still recruiting?

NCT03440970 is currently completed. Last updated 15 September 2025.

Last reviewed 2025-09-15 · How we verify

NCT03440970

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

Completed EARLY_PHASE1 Last updated 15 September 2025

What this trial tests

EARLY_PHASE1 trial testing Lysine Chloride in Decompensated Heart Failure in 20 participants. Completed in 30 August 2025.

Timeline

15 January 2019

Primary endpoint
30 August 2025

30 August 2025

Quick facts

Lead sponsor	Yale University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	diagnostic
Enrollment	20
Start date	15 January 2019
Primary completion	30 August 2025
Estimated completion	30 August 2025
Sites	1 location across United States

Drugs / interventions tested

Lysine Chloride — full drug profile →
Placebo

Conditions studied

Decompensated Heart Failure — all drugs for Decompensated Heart Failure →

Sponsor

Yale University

Who can join

18 and older, any sex, with Decompensated Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to investigate the quantitative effects of sodium-free chloride supplementation on electrolyte balance, volume status, and sodium avidity in stable heart failure patients in a highly controlled environment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure: A U.S. Center's Experience.
Griffin M, Soufer A, Goljo E, Colna M, et al · · 2020 · cited 77× · PMID 32035891 · DOI 10.1016/j.jchf.2019.10.012
Serum Chloride and Heart Failure.
Arora N. · · 2023 · cited 20× · PMID 36911181 · DOI 10.1016/j.xkme.2023.100614
Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure.
Cobo Marcos M, Comín-Colet J, de la Espriella R, Rubio Gracia J, et al · · 2024 · cited 11× · PMID 38380837 · DOI 10.1002/ehf2.14720
Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach.
Rodríguez-Espinosa D, Guzman-Bofarull J, De La Fuente-Mancera JC, Maduell F, et al · · 2022 · cited 8× · PMID 35874534 · DOI 10.3389/fphys.2022.913580

Verify or expand the search:

Other trials of Lysine Chloride

Trials testing the same drug.

NCT03446651 — Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure · EARLY_PHASE1 · completed

Other recruiting trials for Decompensated Heart Failure

Currently open trials in the same condition.

NCT07506499 — Cardiac Rehabilitation in Decompensated Heart Failure · NA · recruiting
NCT07444398 — Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG · Phase 1 · recruiting
NCT06965712 — Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF ) · NA · recruiting
NCT06989580 — BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specif · NA · recruiting
NCT07173426 — Bioimpedance Integration for Optimized Fluid Management in Decompensated Heart Failure · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03440970 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 15 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03440970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing